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umich.edu.The accelerating worldwide use of tobacco products causes
immense human suffering. Smoking tobacco products ulti-
mately kills up to half of its estimated 1 billion worldwide users:
on average, one death every 6 seconds or 5.4 million per year
(World Health Organization, http://www.who.int/tobacco/
mpower/tobacco_facts/en, last accessed on December 10,
2014). Besides its role in cardiovascular and cerebrovascular
diseases and a host of malignancies, tobacco smoking is the
principal cause of chronic obstructive pulmonary disease
(COPD) in the industrialized world. COPD is the only one of
the top 10 leading causes of death that is increasing in
incidence, now occupying the third position in the United
States, and projected by theWorld Health Organization to be
the leading cause of death worldwide within this century.
With the proliferation of new forms of nicotine delivery1,2
that challenge efforts to control tobacco use, there is an
increasing urgency to understand COPD pathogenesis.
In this issue ofTheAmerican Journal ofPathology, Polverino
et al3 report their development of an experimental COPDmodel
in cigarette smoke (CS)-exposed nonhuman primates (NHPs).
This collaboration between research groups at Brigham &
Women’s Hospital (Boston, MA) and the Lovelace Respiratory
Research Institute (Albuquerque, NM) combines pathological,
physiological, and immunological analyses to produce a
comprehensive and interesting report. But even acknowledging
the global importance of understanding COPD pathogenesis,
readers might question whether the expense, requirement for
highly specialized research facilities, and ethical issues sur-
rounding NHP research justify this undertaking. We attempt to
explain why they do and to highlight key features of this novel
model that ﬁll gaps in existing animal models.
The Accelerating Global Disease Burden of COPD
COPD comprises a spectrum of conditions characterized by
incompletely reversible airﬂow obstruction and chronicCopyright ª 2015 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ajpath.2014.12.002respiratory symptoms, but also by signiﬁcant systemic com-
ponents. It encompasses a complex range of lung pathologies,
including emphysema, airway ﬁbrosis, mucus hypersecretion,
and the disappearance of small airways.4 The variable
coexistence of these processes in individuals contributes to
speciﬁc and pleomorphic phenotypes. Once these patholog-
ical process are initiated in susceptible smokers, they gener-
ally progress even after the cessation of active smoking.
Although COPD is manifestly an inﬂammatory condition, it
responds poorly, if at all, to current anti-inﬂammatory agents.
This inexorable progression means that even if every smoker
in the world quit tomorrow, COPD prevalence would
continue to increase for 20 to 40 years. Despite progress in
smoking cessation in most industrialized nations, tobacco use
is increasing rapidly in developing nations.
Worldwide growth of COPD is also driven by air pollu-
tion, especially indoor inhalation of biomass fuel. Inadequate
ventilation of fumes from wood, dung, and lignite used in
cooking and heating results in toxic exposure of an esti-
mated 3 billion individuals, disproportionately women and
children.5 Verifying whether biomass fuel inhalation and
other forms of nonetobacco-related toxic exposures induce
identical pathology and the full range of COPD phenotypes
as induced by CS is an important area of ongoing investi-
gation. Because existing data support the strong similarity
Commentaryof the processes, it is likely that therapeutic advances in
smoking-induced COPD could also beneﬁt the millions in
the developing world who will develop disease from
exposures other than CS.Importance and Limitations of Current Animal
Models of COPD
The inability of current therapies to stop COPD progression
mandates the development of new drugs, a process that
necessarily uses animal models for preclinical testing.
Animal models are also crucial for the bidirectional process
of target discovery: They permit the validation of the
molecular mechanisms identiﬁed as potentially involved in
human disease, and they allow for the generation of novel
hypotheses that can be tested for relevance in human path-
ological specimens.
Models of COPD already exist in multiple animal species.6
Those using mice enjoy the many advantages of that species:
small size, high fecundity, abundant and well-deﬁned genetic
variation between strains, robust transgenic technology, and
unparalleled immunological reagents.7e9 The small size of
mice presented initial challenges for the imaging and mea-
surement of pulmonary function; however, technological
advances including micro computed tomography10 now
permit sophisticated serial nonlethal end points. Murine
CS-exposure models have been highly useful in deﬁning the
effects of smoking on pulmonary immunity11 and the
responses to relevant lung pathogens.12e14 However, without
the addition of microbe challenge, these models tend to pro-
duce rather modest pathological changes, and without addi-
tional manipulations, they do not induce chronic bronchitic
changes. Such deﬁciencies havemotivated the development of
murine models more closely mimicking the full range of
pathological changes found in advanced COPD in humans.
Several groups have done so by combining intrapulmonary
elastase and lipopolysaccharide,10,15 whereas others have
succeeded via transgene expression16 or by combining CS
exposure with innate immune stimulation.17
But murine models of CS-induced COPDwill always have
signiﬁcant, inescapable limitations due to vast differences in
anatomy between rodents and humans. For pathogenesis
studies, the most glaring are the absence of bronchial sub-
mucosal glands, of dichotomously dividing airways or
distinct respiratory bronchioles, and of well-deﬁned lobular
architecture. Moreover, laboratory mice have deﬁned
microbiomes that differ markedly from ours, resulting in
immune responses that similarly differ from those of humans.
And, of course, murine pharmacodynamics and pharmaco-
kinetics, although very well understood, are quite disparate
from those of humans.
To date, no COPD model in larger species has sufﬁcient
advantages imparted by physical size or similarity to human
respiratory anatomy to overcome the deﬁcits of lack of robust
transgenic technology and limitations of immunologicalThe American Journal of Pathology - ajp.amjpathol.orgreagents. However, after the meritorious features of NHPs to
model obstructive airway diseases were reviewed in 2008,18
it was perhaps inevitable that someone would take up the
challenge of developing one via CS exposure.Development of an NHP Model of CS-Induced
COPD
Polverino et al3 describe two series of experiments in female
cynomolgus macaques that realize the promise of an NHP
model of COPD.3 In the ﬁrst, they exposed these NHPs to
CS (or air) for up to 4 weeks, with a goal of detecting the
early changes in lung inﬂammation and mucus metaplasia
that precede overt development of COPD in humans. In the
second series, exposures were lengthened to 12 weeks,
searching for remodeling of small airways, development of
emphysema or intrapulmonary lymphoid aggregates, and
evidence of systemic inﬂammation.
This study used whole-body exposures, the only practical
approach with NHPs, but also one that minimizes stress due to
immobilization and avoidance behaviors that complicate nose-
only exposures in rodents. The exposures at the Lovelace
facility were substantial, which may have contributed to their
success. Estimated doses, calculated based on pulmonary total
suspended particulate matter, approximated humans’ smoking
1.8 and 4 packs per day in the acclimation and target exposure
periods, respectively.
Results show the development of multiple pathological
changes characteristic of human COPD, including mucus
metaplasia in both large (cartilaginous) and smaller airways.
Lung inﬂammation was documented by greater absolute
numbers of neutrophils and macrophages in the broncho-
alveolar lavage ﬂuid, which at 12 weeks’ exposure also
showed elevated concentrations of CCL2 and CXCL8, the key
matrix metalloproteinase MMP-9, and a trend toward
increased IL-6. Lung sections supported these inﬂammatory
changes, both by the accumulation of myeloperoxidase-
positive neutrophils and CD68-positive mononuclear phago-
cytes in distal lung and by the detection of parenchymal
lymphoid aggregates containing germinal centers. Increased
apoptosis of alveolar septal cells was documented by both
TUNEL and cleaved caspase-3 assays.
What This Article Adds
This new experimental model complements rodent models
in several important manners. Signiﬁcant and widespread
bronchial submucosal glandular hypertrophy was achieved.
A particularly interesting ﬁnding is the development of
robust small airway remodeling, an important pathological
change that has been elusive in rodent CS-exposure models
in the absence of additional transgene expression. The
physical size of NHP permits serial testing, including
repeated bronchoalveolar lavage for the analysis of cells
and inﬂammatory mediators, before euthanasia to obtain611
Curtis and Freemanpathological specimens. Such paired analyses reduce sample
sizes while increasing statistical power. Polverino et al3
were able to exploit an important advantage of NHP, the
cross-reactivity of many antibodies with antihuman
reagents, and the model will almost certainly more closely
mimic human physiology than most other nonprimate spe-
cies. The species they studied, Macaca fascicularis, is one
whose genome is being characterized by the Nonhuman
Primate Reference Transcriptome Resource (http://nhprtr.
masonlab.net/website2.html, last accessed December 10,
2014), which should facilitate eventual comparative studies
in patients with COPD.
Limitations and Unanswered Issues
In considering the experimental use of animals for under-
standing human diseases, it is worth distinguishing the
analysis of an animal disease in its natural host (eg, simian
immunodeﬁciency virus in NHPs) versus a simpliﬁed model
system (eg, the smoke-exposure system used by Polverino
et al3). The latter generally does not perfectly capture all
aspects of the corresponding human disease. Hence, it is not
surprising that this model has some limitations. There were
no signiﬁcant differences in pulmonary function, although at
12 weeks there was a nonsigniﬁcant trend toward lower
forced expiratory volume in 0.1 seconds in CS-exposed
NHPs (P Z 0.088). NHPs did not develop signiﬁcant
emphysema in this model. Emphysema was once thought to
develop in only a minority of COPD patients, generally as a
late manifestation of advanced disease. However, this area is
one of several in which the appreciation of the range of human
COPD phenotypes has increased due to newer technologies
and the analysis of cohorts less biased toward severe symp-
toms. Greater use of high-resolution computed tomography
has disclosed that emphysema is more common than previ-
ously suspected and can be substantial in some subjects with
little or no airﬂow obstruction.19,20 Fortunately, emphysema is
a pathological feature well represented in rodent and especially
murine models.
Additionally, Polverino et al3 studied only female NHPs.
Given the important role of sex-speciﬁc differences in COPD
pathologies,21 these experiments should be repeated in male
NHPs. Doing so, perhaps for somewhat longer durations,
might uncover emphysema in male NHPs, as male human
smokers are generally more likely than are female smokers to
develop emphysema.20,22
Probably the greatest limitation of this interesting model is
shared with all CS-exposure models of COPD of which we are
aware. Despite the use of outbred NHPs, pathological changes
appear to be reasonably uniform between the individual ani-
mals. For this reason, it remains unclear whether this model
system will aid in elucidating the most puzzling issue in
COPD pathogenesis: Why do only certain human smokers
develop pathology leading to accelerated loss of lung func-
tion? To date, even large human genomeewide association
studies have not shown that speciﬁc genetic differences612explain the majority of this susceptibility. Exploration of
additional genetic factors, such as noncoding sequences and
epigenetic effects from exposures in previous generations, is
admittedly only beginning, and may ultimately explain this
missing heritability. An intriguing alternative answer to this
central mystery of COPD pathogenesis is that it results from
complex interactions between the particular immune repertoire
of individual smokers (stochastically molded by previous
infections) and their total microbiome (especially in the gut,
the site of greatest contact between our microbes and our
immune systems).The Future
The laboratories of Dr. Yohannes Tesfaigzi (Lovelace
Respiratory Research Institute, Albuquerque, NM) and
Dr. Caroline A. Owen (Brigham and Women’s Hospital,
Boston, MA) are to be congratulated for producing a model
that ﬁlls crucial gaps in the armamentarium of researchers
interested in COPD pathophysiology and treatment.
Although predictions are risky, we anticipate that the
requirement for specialized primate centers and the current
lack of transgenic technology in NHPs may restrict its
widespread use in deﬁning pathophysiological mechanisms.
Instead, we would envision this new model to be most useful
in at least three situations. First, the pharmaceutical industry
might employ it for ﬁnal preclinical testing of novel thera-
peutics, especially biologics, when there is serious concern
that the many disparities between humans and mice could
undermine success. Second, this model might be exceedingly
useful in deconvoluting the effects of comorbid conditions on
COPD phenotypes. Third, the NHP model might be partic-
ularly well suited for the study of microbiomeeimmune
interactions, mentioned in Limitations and Unanswered
Issues. We feel more secure predicting that murine
CS-exposure models will continue to be used productively.
And that is a good thing, as researchers worldwide need
every advantage they can get to combat the scourge of
CS-induced diseases.References
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